Frontier IP Group Plc

Frontier IP Group Plc

0.13
EUR
0.00
(0.00%)
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
Basic EPS, GAAP
-0.04
- -
0.03
0.04
0.04
0.02
0.06
0.09
0.17
0.19
-0.06
-0.02
-0.1
- -
Free Cash Flow per Basic Share
-0.04
-0.03
-0.03
-0.03
-0.04
-0.03
-0.03
-0.04
-0.03
-0.05
-0.06
-0.05
-0.06
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.21
0.18
0.21
0.25
0.31
0.33
0.41
0.51
0.7
0.89
0.82
0.8
0.61
0.53
Tangible Book Value per Share
0.06
0.09
0.13
0.19
0.26
0.28
0.37
0.47
0.66
0.85
0.78
0.76
0.58
0.5
Basic Weighted Avg Shares
10
20
23
28
33
38
41
48
55
55
55
56
63
70
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-165.52
-314.04
-450
-303.17
-309.09
-384.62
-362.2
-448.02
-572.65
-927.66
-779.57
-932.68
-1,038.46
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
1
1
1
1
2
4
10
10
-3
-1
-6
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
6.6
5.97
- -
- -
- -
- -
Profit Margin (%)
-211.49
15.17
380.59
511.76
465.53
301.67
562.2
1,035.64
2,642.54
3,109.42
-872.04
-314.53
-1,952
- -
Working Capital
- -
1
1
1
3
2
2
4
2
5
6
4
4
3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
Total Equity
3
4
6
8
12
13
18
26
38
49
46
45
42
40
Return on Invested Capital (%)
- -
0.79
13.38
17.04
12.61
7.32
15.39
19.12
29.71
23.49
- -
- -
- -
- -
Return on Capital (%)
- -
0.79
13.44
17.1
12.65
7.37
15.51
19.26
29.76
23.48
- -
- -
- -
- -
Return on Common Equity (%)
-14
0.79
13.44
17.1
12.65
7.37
15.51
19.26
29.76
23.48
-6.88
-2.49
-14.62
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
76
Market Capitalization
- -
- -
- -

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
6
5
4
Cash, Cash Equivalents & STI
4
3
2
Accounts Receivable, Net
2
1
2
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.58%
12.19%
-6.19%
Free Cash Flow
21.98%
21.9%
26.94%
Net Income, GAAP
69.74%
80.4%
463.41%
Sales/Revenue/Turnover
7.97%
-3.89%
-9.22%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.1
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Neil David Crabb
Full Time Employees
14
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
78 Cannon Street Edinburgh SC United Kingdom EC4N 6AF
IPO Date
Jan 31, 2011
Business
Frontier IP Group Plc Frontier IP Group Plc specializes in the commercialization of intellectual property derived from universities, academics, and research institutions across the UK, Portugal, and Italy. The company provides advisory services, hands-on commercialization support, technology validation, early industry engagement, and fundraising assistance to spin-out companies; its portfolio spans clusters including artificial intelligence, innovative materials, enabling health, food and agritech, energy, and water technologies, with key portfolio companies such as Cambridge Raman Imaging (graphene-enhanced lasers for imaging), Dekiln (BioSintering for low-carbon ceramic tiles), 2D Photonics (high-speed data solutions), Pulsiv Solar (photovoltaic efficiency enhancements), Alusid (recycled materials mimicking stone), The Vaccine Group (veterinary vaccines), and Amprologix (novel antibiotics). Frontier IP Group Plc maintains operations primarily in the UK with extensions to Europe, targets research institutions and early-stage technology ventures, and is headquartered in London with 21 employees. Founded in 2007 and listed on the AIM market of the London Stock Exchange, the company takes equity stakes in spin-outs in exchange for commercialization services rather than cash, aiming to scale technologies toward market exits. In recent developments, Frontier IP Group Plc entered a strategic partnership in June 2025 with Abstract Mid-Tech Limited to establish an innovation hub in Cambridge, set to open by year-end, enhancing deal flow, portfolio scaling, investor access, and operational efficiency for UK, Italian, and Portuguese companies; portfolio progress includes The Vaccine Group's successful bovine respiratory syncytial virus vaccine trials and Amprologix's fundraising for antibiotic development, alongside Alusid's international distribution agreement.

Company News